Welcome to our dedicated page for FULLER H B CO SEC filings (Ticker: FUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on FULLER H B CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into FULLER H B CO's regulatory disclosures and financial reporting.
H.B. Fuller reported stronger results for the quarter ended May 30, 2026, with net revenue of $950.3 million, up 5.8% from a year earlier, driven mainly by higher pricing and favorable currency.
Gross margin improved to 33.6%, and net income attributable to H.B. Fuller rose to $67.8 million, or $1.23 diluted EPS, versus $0.76 a year ago. Adjusted EBITDA increased 9.3% to $181.0 million. For the first six months, revenue grew 2.0% to $1.72 billion and diluted EPS reached $1.61.
After quarter-end, the company agreed to a recommended cash offer for Advanced Medical Solutions Group plc valuing its share capital at approximately 659,000 British pounds and implying an enterprise value of about 715,000 British pounds. To support the deal, H.B. Fuller arranged bridge credit facilities totaling up to $3.0 billion.
H.B. Fuller reported a stronger second quarter of fiscal 2026, with net revenue of $950 million, up 5.8% from the prior year. Pricing added 3.0% to sales, more than offsetting slightly lower volumes and delivering 2.6% organic revenue growth.
Gross profit rose to $320 million, and adjusted gross margin expanded 200 basis points to 34.2%, helped by pricing execution and restructuring savings. Net income attributable to H.B. Fuller increased to $68 million, with diluted EPS of $1.23. Adjusted EPS reached $1.41, up 19% year-on-year.
Adjusted EBITDA was $181 million, up 9%, while net debt fell to $1.96 billion, reducing net debt-to-adjusted EBITDA to 3.1x. The company generated record second quarter operating cash flow of $121 million and repurchased 750 thousand shares. Based on year-to-date performance, management increased the midpoint of its full-year adjusted EBITDA and adjusted EPS guidance.
FULLER H B CO Executive VP and CFO John J. Corkrean reported updated equity holdings, including a new grant of Phantom Units. He received 195.98 Phantom Units at a reference value of $64.31 per unit, increasing his Phantom Unit balance to 34,423.73 units.
Corkrean also directly holds 59,508 shares of common stock, along with multiple tranches of restricted stock units and employee stock options that are tied to future vesting and expiration dates. The filing shows one compensation-related acquisition and no open-market purchases or sales of FULLER H B CO stock.
H.B. Fuller senior vice president of international growth Heather Campe reported mainly updated holdings, along with a small compensation-related grant. She received 34.640 Phantom Units, which are derivative awards tied to the company’s common stock, valued at $64.31 per unit.
After this grant, she directly holds 24,653.0782 shares of common stock and 5,738.3900 Phantom Units, plus multiple restricted stock unit and stock option awards with exercise prices ranging from $51.89 to $77.72 and expirations between 2028 and 2036. The filing reflects routine equity compensation and position reporting rather than open-market buying or selling.
FULLER H B CO Executive VP and CFO John J. Corkrean reported an update to his equity holdings. The filing shows a grant of 210.48 Phantom Units, each tied 1-for-1 to Fuller common stock, at a reference price of $59.88 per unit under a deferred compensation plan. After this award, he holds 59,508 shares of common stock directly, along with various restricted stock units and employee stock options with exercise prices ranging from about $45.05 to $77.72 per share. This Form 4 reflects routine, compensation-related equity awards rather than any open‑market buying or selling.
Campe Heather reported acquisition or exercise transactions in this Form 4 filing.
FULLER H B CO senior vice president Heather Campe reported a small compensation-related award and updated equity holdings. On June 5, 2026, she received 37.2 Phantom Units at an effective reference price of $59.88 each, bringing her total Phantom Units to 5,703.75. The filing also lists direct holdings of 24,653.0782 shares of common stock and multiple outstanding restricted stock unit and stock option awards that are convertible into common shares over future years.
FULLER H B CO director Teresa J. Rasmussen Trangsrud received a grant of 1,029.960 stock units on May 29, 2026 at $64.0800 per unit. These stock units convert into common stock on a 1-for-1 basis and are scheduled to be converted upon retirement, death, disability, or other specified events under the company plan.
Following this grant, she holds 21,955.710 stock units and 3,391.433 shares of common stock directly, with both figures including amounts accumulated through dividend reinvestment and dividend-equivalent features.
FULLER H B CO director Ruth Kimmelshue reported a compensation-related equity award rather than an open-market trade. She received 514.98 stock units at $64.08 per unit under the Directors' Deferred Compensation Plan, each unit convertible into one share of common stock.
The units convert into common shares upon retirement, death, disability or other specified events under the plan, subject to legal holding periods. Following this grant, she holds 34,014.15 stock units tied to common stock and 1,351 shares of common stock directly.
FULLER H B CO director Michael J. Happe received a grant of stock units as part of director compensation. On 2026-05-29, he was awarded 429.15 stock units at $64.0800 per unit, each convertible into one share of common stock on a 1-for-1 basis.
The filing shows these units will be converted into common shares upon retirement, death, disability or certain specified events under the Directors' Deferred Compensation Plan, subject to required holding periods. After this grant, Happe holds 14,874.29 stock units and 1,343 shares of common stock directly. The Form 4 does not report any open-market purchases or sales, indicating a routine, compensation-related equity award rather than discretionary trading.
FULLER H B CO director Thomas W. Handley reported a compensation grant of stock units. On 2026-05-29, he received 536.44 stock units at $64.08 per unit under the Directors' Deferred Compensation Plan.
After this grant, Handley holds 78,335.7 stock units and 1,347.1 shares of common stock directly. Each stock unit converts into one share of common stock, generally upon retirement, death, disability, or other specified events defined in the plan, subject to required holding periods.